ENvue Medical Inc

Análisis de la acción ENvue Medical Inc (FEED)

$4.310

+0.112 (+2.59%)Al cierre

Loading chart…
High
4.420
Open
4.420
VWAP
4.20
Vol
111.31K
Mkt Cap
Low
3.870
Amount
467.51K
EV/EBITDA, TTM
0.00

ENvue Medical, Inc. is a medical technology company advancing both non-invasive and minimally invasive solutions across clinical and home care settings. Its segments include NanoVibronix, ENvue and Corporate. NanoVibronix is engaged in selling its products directly to patients as well as through distributor agreements. ENvue is engaged in selling its systems and Nasoenteral tubes and related services. The Company focuses on two distinct technology platforms: Acoustic-based therapeutic technologies, including PainShield and UroShield, which utilize proprietary low-intensity surface acoustic wave (SAW) technology. These devices are intended for use in home or care settings and are designed to treat pain, reduce bacterial colonization, and disrupt biofilms. The ENvue Navigation Platform, which is a minimally invasive electromagnetic navigation system intended to assist clinicians in placing feeding tubes into the gastrointestinal tract.

envuemed.com

AI analysis of ENvue Medical Inc (FEED)

sell

ENvue Medical, Inc. is not a good buy right now due to its significantly low price and poor financial performance. The current price is $0.34, and the stock has experienced a year-to-date change of -85.94%. Additionally, the RSI is at 23.926, indicating that the stock is oversold, but this could signal further downside risk rather than a buying opportunity. The company also reported a staggering net income loss of -22,621,000 USD in the most recent quarter, which raises concerns about its financial health.

Métricas de valoración

The current forward P/E ratio for ENvue Medical Inc (FEED) is 0.00, compared to its 5-year average forward P/E of -0.00.

Forward P/E

Strongly Overvalued
5Y Average P/E
-0.00
Current P/E
0.00
Sobrevalorada
-0.00
Infravalorada
-0.00

Forward EV/EBITDA

Strongly Undervalued
5Y Average EV/EBITDA
0.00
Current EV/EBITDA
0.00
Sobrevalorada
0.00
Infravalorada
0.00

Forward P/S

Strongly Undervalued
5Y Average P/S
0.88
Current P/S
0.00
Sobrevalorada
1.04
Infravalorada
0.72

Cronología de eventos

2026-08-10 (ET)

16:30:00

ENvue Medical Files $50M Mixed Securities Shelf

2026-08-04 (ET)

10:00:00

ENvue Medical Completes NanoVibronix Manufacturing Move to the U.S.

2026-07-15 (ET)

08:30:00

ENvue Medical Appoints Zeev Rotstein as Chairman of the Board

2026-05-18 (ET)

17:20:00

ENvue Medical Files to Sell 6M Shares of Common Stock

2026-05-12 (ET)

09:20:00

ENvue Medical Renews Three-Year Contract with Nonprofit Health System

Noticias

FEED FAQ — answered by Alphio AI

ENvue Medical, Inc. is a medical technology company advancing both non-invasive and minimally invasive solutions across clinical and home care settings. Its segments include NanoVibronix, ENvue and Corporate. NanoVibronix is engaged in selling its products directly to patients as well as through distributor agreements. ENvue is engaged in selling its systems and Nasoenteral tubes and related services. The Company focuses on two distinct technology platforms: Acoustic-based therapeutic technologies, including PainShield and UroShield, which utilize proprietary low-intensity surface acoustic wave (SAW) technology. These devices are intended for use in home or care settings and are designed to treat pain, reduce bacterial colonization, and disrupt biofilms. The ENvue Navigation Platform, which is a minimally invasive electromagnetic navigation system intended to assist clinicians in placing feeding tubes into the gastrointestinal tract. It operates in the Healthcare sector.

ENvue Medical, Inc. is not a good buy right now due to its significantly low price and poor financial performance. The current price is $0.34, and the stock has experienced a year-to-date change of -85.94%. Additionally, the RSI is at 23.926, indicating that the stock is oversold, but this could signal further downside risk rather than a buying opportunity. The company also reported a staggering net income loss of -22,621,000 USD in the most recent quarter, which raises concerns about its financial health.

Esta página es solo para investigación y no constituye asesoramiento de inversión. Los modelos pueden equivocarse. El rendimiento pasado no garantiza resultados futuros.

Empieza gratis